EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Laninamivir and its Prodrug, CS-8958: Long-Acting Neuraminidase Inhibitors for the Treatment of Influenza

Makoto Yamashita

Antiviral Chemistry and Chemotherapy · 2010-12 · 21 (2) · 71-84

DOI: 10.3851/imp1688 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Antiviral Chemistry and Chemotherapy, online erschienen am 01.12.2010. Verfasst von Makoto Yamashita. Beteiligte Einrichtung: Biological Research Laboratories, Daiichi Sankyo Co., Ltd, Tokyo, Japan. yamashita.makoto.yr@daiichisankyo.co.jp. Hauptthemen laut MEDLINE: Influenza, Human, Neuraminidase. Die Arbeit wurde bisher 96-mal zitiert (Crossref) und nennt 47 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Oseltamivir and zanamivir are currently licensed worldwide for influenza treatment and chemoprophylaxis. Both drugs require twice-daily administration for 5 days for treatment. A new influenza drug, laninamivir (code name R-125489), and its prodrug form, CS-8958 (laninamivir octanoate or laninamivir prodrug), which are long-acting neuraminidase inhibitors, are introduced in this review. Laninamivir potently inhibited the neuraminidase activities of various influenza A and B viruses, including subtypes N1–N9, pandemic (2009) H1N1 virus, highly pathogenic avian influenza (HPAI) H5N1 viruses and oseltamivir-resistant viruses. Because of the long retention of laninamivir in mouse lungs after an intranasal administration of CS-8958, therapeutic administration of a single dose of CS-8958 showed superior efficacy to repeated administrations of zanamivir or oseltamivir in animal infection models for influenza A and B viruses. These include pandemic (2009) H1N1 virus and HPAI H5N1 virus. Prophylactic single administration of CS-8958, as early as 7 days prior to infection, also showed superior efficacy. Finally, the potential of a single inhalation of CS-8958 for influenza patients was demonstrated by clinical studies, and CS-8958 has been approved and is commercially available as Inavir® (Daiichi Sankyo Co., Ltd, Tokyo) in Japan.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Influenza, HumanNeuraminidaseAnimalsAntiviral AgentsDisease Models, AnimalDrug Administration RoutesDrug Administration ScheduleGuanidinesHumansMiceOrthomyxoviridaeOseltamivirPandemicsProdrugsPyransRatsSialic AcidsZanamivir

Substanzen

Antiviral AgentsCS 8958GuanidinesProdrugsPyransSialic AcidsOseltamivirlaninamivirNeuraminidaseZanamivir

Autor:innen und Institutionen

  • Biological Research Laboratories, Daiichi Sankyo Co., Ltd, Tokyo, Japan. yamashita.makoto.yr@daiichisankyo.co.jp

Zitieren

APA

Yamashita, M. (2010). Laninamivir and its Prodrug, CS-8958: Long-Acting Neuraminidase Inhibitors for the Treatment of Influenza. Antiviral Chemistry and Chemotherapy, 21(2), 71-84. https://doi.org/10.3851/imp1688

Vancouver

Yamashita M. Laninamivir and its Prodrug, CS-8958: Long-Acting Neuraminidase Inhibitors for the Treatment of Influenza. Antiviral Chemistry and Chemotherapy. 2010;21(2):71-84. doi:10.3851/imp1688

BibTeX
@article{Yamashita2010,
  author = {Yamashita, Makoto},
  title = {Laninamivir and its Prodrug, CS-8958: Long-Acting Neuraminidase Inhibitors for the Treatment of Influenza},
  journal = {Antiviral Chemistry and Chemotherapy},
  year = {2010},
  volume = {21},
  number = {2},
  pages = {71--84},
  doi = {10.3851/imp1688}
}
Kostenlos starten →